Skip to main content

Selzman Lab

The Selzman Lab

Testing heart samples in lab

The Selzman lab at the University of Utah is seeking to examine the role of inflammation in cardiac remodeling, as well as the transcriptional regulation and mechanisms of myocardial recovery, in models of pressure overload and ischemia-reperfusion injury. To investigate this, our team uses several in vitro and in vivo models, ranging from individual cardiomyocytes to transgenic mice, rats, as well as larger translational studies in swine and humans.

Research

The Selzman lab focuses on understanding the effect of novel therapies on different cardiovascular diseases and ischemia-reperfusion injury.

Transcriptional regulation in cardiac remodeling 

  • The lab studies transcription factors such as nuclear factor kappa B (NF-κB) and their role in mediating pathologic cardiac hypertrophy and heart failure. 
  • This work is important because identifying key regulatory pathways may lead to targeted therapies that reverse heart failure rather than only manage symptoms. 

Metabolic and molecular mechanisms of myocardial recovery 

  • Research includes investigation of cardiac metabolism (e.g., pyruvate-lactate axis, glucose metabolism pathways) and how these pathways influence recovery after mechanical unloading (e.g., LVAD support). 
  • The lab integrates findings from human tissue, animal models, and cellular systems to identify therapeutic targets that promote recovery of the failing heart. 

Utah Cardiac Recovery Group (UCAR)

  • The Utah Cardiac Recovery Program (UCAR) is a multidisciplinary clinical and laboratory research. UCAR’s research priorities evolve in close coordination with its clinical programs, creating a continuous, bidirectional exchange in which scientific discovery informs patient care and clinical experience guides further investigation. This integrated approach strengthens both the program’s research capabilities and its clinical impact.
  • Our lab is involved in research related to cardiac remodeling due to adverse molecular and structural myocardial changes, particularly in the setting of heart failure. Our goal is to determine established and novel therapies that can lead to ‘reverse remodeling’ to improve heart function

Effect of human amniotic fluid in models of myocardial infarction and ischemia-reperfusion injury

  • Our lab has investigated the anti-inflammatory and immunomodulatory effects of human amniotic fluid in cardiovascular diseases, and others have shown promising results treating burns and chronic inflammatory diseases. We have shown that human amniotic fluid is a promising therapeutic option for cardiovascular disease demonstrated by preserved heart function and myocardial structure in models of ischemic heart failure and ischemia-reperfusion injury.

PRINCIPAL INVESTIGATOR

Craig H. Selzman, MD, is an established surgeon-scientist whose research focuses on understanding the mechanisms of heart failure and developing new strategies to restore cardiac function. As an Investigator at the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) at the University of Utah, he leads clinical, basic science, and translational research.

His research interests include:

  • Advanced heart failure and heart transplantation
  • Ventricular assist devices and mechanical circulatory support
  • Myocardial recovery and reverse cardiac remodeling
  • Cardiac metabolism and molecular mechanisms of heart failure
  • Ischemia-reperfusion injury
  • Inflammation and transcriptional regulation in cardiovascular disease
  • Novel therapies to promote cardiac recovery
  • Clinical trials in heart support and transplantation technologies

Dr. Selzman leads an NIH-funded translational research laboratory that uses laboratory investigations, animal models, and human cardiac tissue to study the cellular, molecular, and metabolic processes involved in heart failure and recovery.

A central focus of his research is understanding why some patients with advanced heart failure regain cardiac function following mechanical circulatory support, including LVAD therapy. By identifying the biological mechanisms behind myocardial recovery, his team aims to develop treatments that could help more patients recover heart function. This work has contributed to the development of the Utah Cardiac Recovery Program.

Dr. Selzman also participates in clinical research evaluating next-generation cardiac support and transplantation technologies, including the BrioVAD system, HeartMate 3 ventricular assist devices, and advances in donor heart preservation. His research also examines ischemia-reperfusion injury and potential therapies to reduce cardiac damage and improve recovery.

Through an extensive body of peer-reviewed research, Dr. Selzman continues to advance our understanding of heart failure, mechanical circulatory support, and the potential for recovery in patients with advanced heart disease.

Team

Working with Craig Selzman, MD, is a multidisciplinary team of scientists, trainees, and collaborators within the Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI) and the Utah Cardiac Recovery Program. 

Working with Craig Selzman, MD, are scientists:

  • Grace Mitchell, MD, PhD – Research Assistant Professor
  • Douglas Smego, MD – Professor
  • Carla Valenzuela Ripoll, MD – Postdoctoral Research Associate
  • Jan Pierce, MBA – Cell Therapy & Regenerative Medicine Senior Director

Collaborative investigators and trainees 

  • The lab works closely with cardiovascular researchers, surgeons, and physician-scientists studying cardiac metabolism, remodeling, and recovery. 
  • Team members contribute to experimental design, animal models, molecular biology studies, and translational clinical research. 
Heart muscle samples under a microscope

Highlighted Publications

Contact Us

LAB

Selzman Lab
Division of Cardiothoracic Surgery
Nora Eccles Harrison Cardiovascular Research & Training Institute (CVRTI)
University of Utah

Email: Craig.Selzman@hsc.utah.edu 
Address: 95 S 2000 E, Salt Lake City, UT 84112 

CLINICAL TRIALS

Email: margaret.carlson@hsc.utah.edu

Address: 30 N Mario Capecchi Dr 4N145, Salt Lake City, UT 84112